key: cord-0780498-qismdwg1
authors: Nwajei, Felix; Anand, Pria; Abdalkader, Mohamad; Arasa, Vanesa C. Andreu; Aparicio, Hugo J.; Behbahani, Siavash; Curiale, Gioacchino; Daneshmand, Ali; Dasenbrock, Hormuzdiyar; Mayo, Thomas; Mian, Asim; Nguyen, Thanh; Ong, Charlene; Romero, J. Rafael; Sakai, Osamu; Takahashi, Courtney; Cervantes-Arslanian, Anna M.
title: Cerebral Venous Sinus Thromboses in Patients with SARS-CoV-2 Infection: Three Cases and a Review of the Literature
date: 2020-10-19
journal: J Stroke Cerebrovasc Dis
DOI: 10.1016/j.jstrokecerebrovasdis.2020.105412
sha: 5693914aca8ee09555bf905c2ca2fd3306c948b6
doc_id: 780498
cord_uid: qismdwg1

INTRODUCTION: : Early studies suggest that acute cerebrovascular events may be common in patients with coronavirus disease 2019 (COVID-19) and may be associated with a high mortality rate. Most cerebrovascular events described have been ischemic strokes, but both intracerebral hemorrhage and rarely cerebral venous sinus thrombosis (CVST) have also been reported. The diagnosis of CVST can be elusive, with wide-ranging and nonspecific presenting symptoms that can include headache or altered sensorium alone. OBJECTIVE: : To describe the presentation, barriers to diagnosis, treatment, and outcome of CVST in patients with COVID-19. METHODS: : We abstracted data on all patients diagnosed with CVST and COVID-19 from March 1 to August 9, 2020 at Boston Medical Center. Subsequently, we reviewed the literature and extracted all published cases of CVST in patients with COVID-19 from January 1, 2020 through August 9, 2020 and included all studies with case descriptions. RESULTS: : We describe the clinical features and management of CVST in 3 women with COVID-19 who developed CVST days to months after initial COVID-19 symptoms. Two patients presented with encephalopathy and without focal neurologic deficits, while one presented with visual symptoms. All patients were treated with intravenous hydration and anticoagulation. None suffered hemorrhagic complications, and all were discharged home. We identified 12 other patients with CVST in the setting of COVID-19 via literature search. There was a female predominance (54.5%), most patients presented with altered sensorium (54.5%), and there was a high mortality rate (36.4%). CONCLUSIONS: : During this pandemic, clinicians should maintain a high index of suspicion for CVST in patients with a recent history of COVID-19 presenting with non-specific neurological symptoms such as headache to provide expedient management and prevent complications. The limited data suggests that CVST in COVID-19 is more prevalent in females and may be associated with high mortality.

Early reports suggest that neurologic complications are frequent in patients with coronavirus disease , occurring in 36% to 65% of hospitalized patients (1, 2) .

While early reports described stroke as a complication seen primarily in critically ill patients, up to 5% in a cohort from Wuhan (1), other studies have described many cases of stroke in COVID- 19 patients from the community (3) . Cerebral venous sinus thrombosis (CVST) is a rare form of stroke (<1%), caused by occlusion of the dural venous sinuses and/or cerebral veins (4) . Clinical presentation may be highly variable, with symptoms ranging from headache, visual complaints, or nausea to focal deficits or seizure. Though death with CVST is uncommon in patients without COVID-19 (3-15%) (5), neurologic deterioration is common (23%) (6) . Risk factors for CVST are similar to those for other forms of venous thromboembolism, including pro-thrombotic state and trauma. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thought to cause endothelial injury specifically through binding with angiotensin converting enzyme 2 (ACE-2) receptors, activating a cytokine cascade and leading to a hypercoagulable state (7) . Though systemic venous thromboembolism has been commonly reported in COVID-19 infection, cases of CVST are less frequently described in the literature (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .

Here, we describe the presentation of 3 patients with COVID-19 diagnosed with CVST, discuss management considerations, and review published literature on patients with COVID-19 and CVST.

This was a single-center retrospective study at an urban, safety-net, academic hospital in Massachusetts, approved by the Boston Medical Center Institutional Review Board. Data on CVST in patients with COVID-19 were abstracted from the electronic medical record system from March 1 to August 9, 2020. The literature on CVST in patients with COVID-19 was reviewed on August 9, 2020 by searching the terms "cerebral venous sinus thrombosis AND COVID-19" or "CVST AND COVID-19" or "Stroke AND COVID-19." We manually searched the bibliography of studies obtained to extract additional published cases. Only studies with case descriptions were included.

A healthy 68-year-old woman presented with fever, cough, and shortness of breath. A nasopharyngeal swab RT-PCR test resulted positive for SARS-CoV-2. She was hospitalized for two days, then discharged home. Three weeks later, she returned with four days of nausea, vomiting, generalized weakness, and headache ( Table 1) . Her neurologic exam revealed only disorientation to place and time, and her laboratory workup showed increased inflammatory markers. CT venogram (Figure 1 ) revealed filling defects within major venous structures including posterior superior sagittal sinus and torcula, straight sinus, the vein of Galen, inferior sagittal sinus, the internal cerebral veins, and bilateral transverse sinuses. MRI demonstrated abnormal susceptibility artifact interdigitating within the sulci of the bilateral posterior frontal, parietal, and occipital lobes suggestive of cortical vein thrombosis, and T2/FLAIR hyperintensity within the same regions suggestive of venous congestion. Repeat nasopharyngeal swab RT-PCR test for SARS-CoV-2 was negative.

She was started on dose-adjusted unfractionated intravenous heparin, later transitioned to enoxaparin, followed by dabigatran. On the second night of hospitalization, she had a focal seizure confirmed on electroencephalography and was treated with levetiracetam and lacosamide. Her mental status improved, and she was discharged home.

A 79-year-old woman with hypertension presented with fever, nausea, vomiting, and diarrhea ( Table 1) . She tested positive for SARS-CoV-2 via nasopharyngeal swab RT-PCR and was started on azithromycin and hydroxychloroquine. On day 3 of hospitalization, she was disoriented and reported headaches, but had no focal neurologic deficits. CT venogram revealed a curvilinear thrombus within the right transverse sinus (Figure 2) . She was started on therapeutic low-molecular-weight heparin. Her mental status improved with correction of her metabolic derangements, and she was discharged home on enoxaparin.

A 25-year-old woman with Evans Syndrome, idiopathic thrombocytopenic purpura on avatrombopag, von-Willebrand Disease, and a history of multiple intracerebral hemorrhages presented with intractable headache, blurry vision, and tingling of the right upper extremity ( Table 1) . She tested positive for SARS-CoV-2 via nasopharyngeal swab RT-PCR 4 months prior but was negative upon repeat testing. MR venogram demonstrated superior sagittal sinus thrombosis and bilateral transverse sinus thrombosis. She was started on dose-adjusted unfractionated intravenous heparin and transitioned to apixaban. Her immunotherapy was also changed to fostamatinib for its lower risk of prothrombotic events.

We identified 12 patients with COVID-19 and CVST in the published literature and extracted data for 11 patients for whom detailed case descriptions were available (8, (10) (11) (12) (13) (14) (15) (16) (17) .

Clinical data are summarized in Table 1 . Patients ranged between 29 and 72 years old, with 54.5% female (n=6). The majority (7, 63.6%) of patients did not have any underlying comorbidities, and 9 (81.8%) were not taking any prescribed medications prior to presentation. The most common presenting symptom was altered sensorium (6, 54.5%). The COVID diagnosis preceded identification of CVST diagnoses by 4 days to 2 weeks. Thromboses were visualized most frequently in the straight and left transverse sinuses (5, 45.5%). Of the reported patient outcomes, 4 (36.4%) died during admission and treatment for CVST.

We describe three cases of CVST in women with COVID-19, all of whom survived with favorable neurologic outcomes. We additionally identified detailed case descriptions of 11 other patients in the literature (6 women) including 4 deaths. Though we cannot attribute causality, we suspect COVID-19 infection may increase the risk for development of CVST, especially in those with other predisposing risk factors.

Patients who developed CVST in this series all exhibited symptoms of COVID-19. These included a febrile illness with respiratory symptoms, although one patient initially had gastrointestinal complaints, also commonly seen with COVID-19. It is unclear whether symptoms of nausea, vomiting, and resultant dehydration contributed to or resulted from CVST in this patient.

At least 2 patients from our 3 had other major contributing factors for the development of CVST. One patient had an underlying malignancy, breast cancer, and another had Evans syndrome. Few cases of COVID-19 have been reported to occur in the setting of Evans syndrome, complicating the interpretation of CVST in this patient (19, 20) . Our patient had been diagnosed with Evans syndrome approximately 8 years prior, with no interval thromboembolic events despite additional therapeutic predisposing factors, including avatrombopag. Therefore, we think it is possible that COVID-19 decreased the threshold for the development of CVST in this patient in the setting of her underlying predisposition.

Though two of the patients included in our case series had initial SARS-CoV-2 testing which was positive during initial infection and negative at the time of presentation for CVST, we suspect COVID-19 infection may still have been a provoking factor. Given the myriad of reports of persistent symptoms weeks to months after initial infection, it is plausible that a prothrombotic state also lingers after acute infection (21) (22) (23) . Consistent with this hypothesis, studies during prior coronavirus pandemics have found that patients have been shown to harbor leukocytes that are persistently infected two months after initial infection with coronavirus that could potentially be pro-inflammatory (22, 24) . The majority of patients in our series were found to have elevated inflammatory markers. Given that abundant evidence has demonstrated increased rates of thromboembolic events in the setting of SARS-CoV-2 (25, 26), we posit that SARS-CoV-2 infection itself predisposes patients to the development of CVST. The presence of a pro-thrombotic state in the post-acute phase of infection is not unique to COVID-19, as the majority of venous thromboembolic events (VTEs) post-acute illness occurs in the first 30 days following hospital discharge (27) . As such, current guidance suggests a continuation of thromboprophylaxis up to 45 days following discharge for some COVID-19 patients (28) (29) (30) .

Reports from China and Europe suggest a similar prevalence of SARS-CoV-2 infection between men and women but differences in disease severity, with a higher global rate of hospitalization and deaths among male patients (31, 32) . In our study and the published literature, women with COVID-19 appeared to be at higher risk for CVST, similar to data in non-COVID-19 patient populations (33) . It is important to highlight, as women overall may experience a headache more frequently as a symptom of COVID-19 or have a history of migraine disorder, which may lower clinician's suspicion for this critical pathology (34) .

Gender-specific risk factors including oral contraceptives, pregnancy, puerperium, and hormone replacement therapy are thought to facilitate the development of CVST (33) . During a prior coronavirus pandemic, estrogen was shown to protect against SARS by activating an immune response and inhibiting SARS-CoV replication (35) . It is hypothesized that a similar mechanism could occur in patients with COVID-19 (36) . We hypothesize that the same strong and protective Diagnosis of CVST in this patient population may be particularly challenging given that preliminary reports suggest that neurological symptoms are quite common, including headache in 5.6% to 70.3% and encephalopathy in 7.5% to 84.3% (1, (37) (38) (39) . These non-specific neurological symptoms may obscure the early presenting findings of CVST in patients with COVID-19, particularly in those with a critical illness where toxic-metabolic derangement is common. Seizure may also be a common presenting symptom in patients with COVID-19, even in those without prior history of epilepsy (40) . In patients with COVID-19 presenting with headache, mental status deterioration, or seizure, CVST should be suspected even in the absence of focal neurological deficits. In our series, symptoms suggestive of CVST occurred days to months after the initial diagnosis of COVID-19, highlighting the variability of symptom onset, and similar to the timeline of presentation of other cerebrovascular events in some patients with COVID-19 (41) . Increasing reports suggest a longer duration of illness in some patients than (44) . Furthermore, patients with acute respiratory distress syndrome or refractory hypoxemia may also be unable to tolerate aggressive hydration (45) (46) (47) .

The diagnosis, monitoring, and treatment of CVST may present unique challenges in patients with COVID-19. Given the hypercoagulability associated with SARS-CoV-2 infection, CVST should be considered within the differential diagnosis in patients with COVID-19 with headache, encephalopathy, seizure, or focal neurologic deficit. Women may be at higher risk for development of CVST associated with SARS-CoV-2 infection. Larger studies are needed to guide therapy in this population. 

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurological Manifestations in Critically Ill Patients With COVID-19: A Retrospective Study

Intravenous tPA for Acute Ischemic Stroke in Patients with COVID-19

Thrombosis of the cerebral veins and sinuses. The New England journal of medicine

Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis

Prognosis of cerebral vein thrombosis presenting as isolated headache: early vs. late diagnosis. Cephalalgia : an international journal of headache

COVID-19 and its implications for thrombosis and anticoagulation

Venous thromboembolism in COVID-19 patients

First case of Covid-19 presented with cerebral venous thrombosis: A rare and dreaded case

Cerebral Venous Thrombosis Associated with COVID-19

Cerebral venous thrombosis: A typical presentation of COVID-19 in the young

Atypical Deep Cerebral Vein Thrombosis with Hemorrhagic Venous Infarction in a Patient Positive for COVID-19

Venous cerebral thrombosis in COVID-19 patient

A Case of Coronavirus Disease 2019 Presenting with Seizures Secondary to Cerebral Venous Sinus Thrombosis

COVID-19-associated acute cerebral venous thrombosis: clinical, CT, MRI and EEG features

Mortality of cerebral venous-sinus thrombosis in a large national sample

Evans syndrome in a patient with COVID-19

Evans syndrome associated with antiphospholipid antibodies in a patient with SARS-COV-2 infection

Persistent Symptoms in Patients After Acute COVID-19

Neuroinvasion by human respiratory coronaviruses

Cerebral Micro-Structural Changes in COVID-19 Patients -An MRI-based 3-month Follow-up Study

Activation of human monocytes after infection by human coronavirus 229E

COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thrombosis and haemostasis

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009)

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

Emergence of institutional antithrombotic protocols for coronavirus 2019

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis

Impact of sex and gender on COVID-19 outcomes in Europe

Biological sex impacts COVID-19 outcomes

Cerebral venous and sinus thrombosis in women

Clinical and epidemiological characteristics of 1420 European patients with mild-tomoderate coronavirus disease 2019

Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection

ACE2 expression and sex disparity in COVID-19

Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis

Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients

Seizure as the presenting symptom of COVID-19: A retrospective case series

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol

Persistent Symptoms in Patients After Acute

Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features

Hemorrhagic stroke and anticoagulation in COVID-19

Endovascular mechanical thrombectomy for cerebral venous sinus thrombosis: a systematic review

Mechanical thrombectomy in cerebral venous thrombosis: systematic review of 185 cases

Indications for the Performance of Intracranial Endovascular Neurointerventional Procedures: A Scientific Statement From the